Niacor
(Niacin)ApprovedSmall molecule
AbbVieNiacin is used to lower cholesterol and triglycerides (fatty substances in the blood) to help reduce heart disease risk, and it's also used to treat niacin deficiency. It can help improve your heart health by raising good cholesterol and lowering bad cholesterol.[2] Niacor is currently approved and in use across 53 indications[4].[1]
Niacor is one of 1139 small molecule programs targeting Insulin resistance. It is currently in Approved.
53
Indications
63
Total Trials
12
Active Trials
1,138
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 53 indications
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Niacor
AbbVieApproved
Actemra
RochePreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Kineret
SSwedish Orphan Biovitrum
Preclinical
Cataflam
NovartisPreclinical
Rituxan
PfizerPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Vancocin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atherosclerosis6 trials
Endothelial Function5 trials
Hyperphosphatemia2 trials
Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients
Enrolling by invitation·—·Phase 2/3·NCT06406140·50 enrolled
The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis
Unknown status·—·Phase 4·NCT03163576·150 enrolled
Trial2 trials
40 more indications
Flushing2 trials
Psilocybin2 trials
Coronary Artery Disease2 trials
Cholesterol1 trial
Drug1 trial
Heart Disease1 trial
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
Completed·—·N/A·NCT00246376·221 enrolled
Cardiovascular Disease1 trial
Irritable Bowel Syndrome1 trial
Diabetic Nephropathy1 trial
Ischemic stroke1 trial
Post-Traumatic Stress Disorder1 trial
Immune1 trial
Niacin on Immune Activation : a Proof-of-concept Study
Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT02018965·16 enrolled
Efficacy1 trial
Type 2 Diabetes Mellitus1 trial
Prospective1 trial
Lip1 trial
Elevated Cholesterol1 trial
Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00046267·30 enrolled
Magnetic Resonance Imaging1 trial
Effectiveness1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
WAMPOCAP
NDA NDA011073
Jul 28, 1997
NIASPAN
NDA NDA020381
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Niacor drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Niacin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]